Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
A pilot study designed to reveal the effects of Marinol / dronabinol, a CB 1 agonist. Primary end point: To estimate weight gain and EDI scores in patients receiving Marinol compared to placebo Secondary end points: Motor and inner restlessness and hormonal changes during the treatment.
Epistemonikos ID: 5f7e0152896ee56f39476efd1771ae6fb6a6f256
First added on: Apr 23, 2019